Type 2 Diabetes Mellitus
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Effect of Saxagliptin On the Incidence of Cardiovascular Death, Myocardial Infarction Or Ischemic Stroke in Patients with Type 2 Diabetes
To determine whether Saxagliptin can reduce the risk of cardiovascular events when used alone or added to other diabetes medication.
Key Inclusion Criteria
Patients with Type 2 Diabetes, a HbA1c > 6.5%, who also have established cardiovascular disease and/or multiple risk factors
Key Exclusion Criteria
Current or previous (within 6 months) treatment with DPP4 inhibitors and/or GLP-1 mimetics, acute vascular event less than 2 months prior to randomization